m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG00042)
Name
LY2157299
Synonyms
Galunisertib; 700874-72-2; LY2157299; LY 2157299; LY-2157299; UNII-3OKH1W5LZE; 4-(2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 3OKH1W5LZE; Galunisertib (LY2157299); AK-79916; 4-[5,6-Dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6-quinolinecarboxamide; 4-(2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo-[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 4-[2-(6-methylpyridin-2-yl)-4H,5H,6H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-6-carboxamide
    Click to Show/Hide
Status
Phase 2/3
Structure
Formula
C22H19N5O
InChI
1S/C22H19N5O/c1-13-4-2-5-18(25-13)21-20(19-6-3-11-27(19)26-21)15-9-10-24-17-8-7-14(22(23)28)12-16(15)17/h2,4-5,7-10,12H,3,6,11H2,1H3,(H2,23,28)
InChIKey
IVRXNBXKWIJUQB-UHFFFAOYSA-N
PubChem CID
10090485
TTD Drug ID
D06TFI
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Transforming growth factor beta 1 (TGFB1)
Eukaryotic initiation factor 3 (EIF3A)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Transforming growth factor beta 1 (TGFB1) is a therapeutic target for LY2157299. The Eukaryotic initiation factor 3 (EIF3A) has potential in affecting the response of LY2157299 through regulating the expression of Transforming growth factor beta 1 (TGFB1). [1], [2]
Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Transforming growth factor beta 1 (TGFB1) is a therapeutic target for LY2157299. The Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) has potential in affecting the response of LY2157299 through regulating the expression of Transforming growth factor beta 1 (TGFB1). [2], [3]
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Transforming growth factor beta 1 (TGFB1) is a therapeutic target for LY2157299. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of LY2157299 through regulating the expression of Transforming growth factor beta 1 (TGFB1). [2], [4]
YTH domain-containing family protein 2 (YTHDF2)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Transforming growth factor beta 1 (TGFB1) is a therapeutic target for LY2157299. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of LY2157299 through regulating the expression of Transforming growth factor beta 1 (TGFB1). [2], [5]
References
Ref 1 Knockdown of elF3a inhibits TGF?Beta1?induced extracellular matrix protein expression in keloid fibroblasts. Mol Med Rep. 2018 Mar;17(3):4057-4061. doi: 10.3892/mmr.2017.8365. Epub 2017 Dec 29.
Ref 2 Clinical pipeline report, company report or official report of Tissue Gene, Inc.
Ref 3 HNRNPA2B1, as a m(6)A Reader, Promotes Tumorigenesis and Metastasis of Oral Squamous Cell Carcinoma. Front Oncol. 2021 Sep 23;11:716921. doi: 10.3389/fonc.2021.716921. eCollection 2021.
Ref 4 N6-Methyladenosine Regulates the Expression and Secretion of TGFBeta1 to Affect the Epithelial-Mesenchymal Transition of Cancer Cells. Cells. 2020 Jan 25;9(2):296. doi: 10.3390/cells9020296.
Ref 5 YTHDF2 Inhibits the Migration and Invasion of Lung Adenocarcinoma by Negatively Regulating the FAM83D-TGFBeta1-SMAD2/3 Pathway. Front Oncol. 2022 Feb 2;12:763341. doi: 10.3389/fonc.2022.763341. eCollection 2022.